[opensourcepharma] Marburg Meeting and Open Source Pharma Items

Sat Sep 5 07:35:17 UTC 2015

All,

The 2nd Open Source Pharma Meeting just closed here in Germany. Follow-up
action and coordination items will be coming to the participants (derived
from the raw notes <http://tinyurl.com/OSP2Final>). For everyone else you
can see some of the activity at the meeting on the OSP Twitter feed
<https://twitter.com/OSPInfo>. In what must be a speed record, one of the
participants, Andy Updegrove, has already posted an informative blog post
<http://www.consortiuminfo.org/standardsblog/article.php?story=20150904123645851>
on the meeting intended for people unfamiliar with the concept.

Other items:

1. Repurposing for schistosomiasis
<http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0003962>
from DNDi and Jenny Keiser

2. An analysis
<http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0134898>
of how people respond to prize-based science competitions (here,
Innocentive): "women and older participants have significantly less fear of
disclosing their scientific knowledge"

3. A new offering from Lilly
<https://openinnovation.lilly.com/dd/what-we-offer/synthesis.html> for
collaborations in automated synthesis that might be useful for a number of
projects.

4. An article
<https://www.jisc.ac.uk/blog/open-science-many-hands-make-light-work-17-aug-2015>
on the importance of open science to the forthcoming Dutch presidency of
the EU.

5. Collaboration
<http://www.thesgc.org/news/toronto/ontario-institute-cancer-research-and-structural-genomics-consortium-develop-and-give>
between the SGC and the Ontario Institute for Cancer Research on OICR-9429.

6. For the software people: a debate
<https://danielskatzblog.wordpress.com/2015/08/27/the-price-of-open-source-software-a-joint-response/>
about how we should develop software for science, e.g. whether open source
and whether it should be free.

7. A company I wasn't aware of, Transcriptic
<https://www.transcriptic.com/product/>, that is doing remote, "dial-in"
life science experiments.

8. Community cooperation in a website to track the quality and clarify the
function (and hence the correct use) of chemical probes. Paper
<http://www.nature.com/nchembio/journal/v11/n8/full/nchembio.1867.html>,
article
from ICR
<http://www.icr.ac.uk/blogs/the-drug-discoverer/page-details/ensuring-biomedical-research-is-gold-standard-through-better-use-of-chemical-probes>.

9. Article <http://www.nature.com/nrd/journal/v14/n9/full/nrd4706.html>
about the CO-ADD antibiotic screening facility in Queensland.

10. Using the SGC as an example, a study
<http://www.sciencedirect.com/science/article/pii/S0048733314002248> on how
"boundary organisations" can help companies deal with open data initiatives.

11. In case you missed it the Economist going to town on patents (here
<http://www.economist.com/news/leaders/21660522-ideas-fuel-economy-todays-patent-systems-are-rotten-way-rewarding-them-time-fix>,
here <http://www.economist.com/node/21660559>) and Derek Lowe's take
<http://blogs.sciencemag.org/pipeline/archives/2015/08/13/the-problem-with-patents>.
Article
<http://www.bioprocessonline.com/doc/rare-diseases-and-intellectual-property-creative-ip-strategies-0001>
from the Rare Genomics Institute on creative IP policies.

12. A recent paper
<http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2641815> on An
International Legal Framework to Address Antimicrobial Resistance

13. A collection of US doctors advocating
<http://www.mayoclinicproceedings.org/article/S0025-6196%2815%2900430-9/fulltext>
for lower cancer drug prices.

A very tentative save the date. There are suggestions we might hold a 3rd
Open Source Pharma meeting at the end of September 2016 in Silicon Valley.
If anyone has any particular positive or negative views on that (and
possible host locations that can compete with Lake Como or a German castle)
then please let me know.

Many of us are in Basel this coming week for ECTMIH - there is an
interesting session
<http://www.professionalabstracts.com/ectmih2015/planner/index.php?go=cp&sessID=72>
on open source at 1:30 on Monday 7th.

A reminder, particularly given that several people have recently signed up:
this email list is available for anyone to share items of interest or to
start overview discussions related to open source approaches to pharma.
Please work on the principle that we all already receive too many emails
(i.e. this list is not a chatroom), and please remember that the archive of
all mails sent is public.

Best wishes everyone,

Mat

-- 
MATTHEW TODD | Associate Professor
School of Chemistry | Faculty of Science

THE UNIVERSITY OF SYDNEY
Rm 519, F11 | The University of Sydney | NSW | 2006
T +61 2 9351 2180  | F +61 2 9351 3329  | M +61 415 274104
E matthew.todd at sydney.edu.au | W
http://sydney.edu.au/science/people/matthew.todd.php
W http://opensourcemalaria.org/ | W http://opensourcetb.org/ | W
http://opensourcepharma.net/

CRICOS 00026A
This email plus any attachments to it are confidential. Any unauthorised
use is strictly prohibited. If you receive this email in error, please
delete it and any attachments.
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.okfn.org/pipermail/opensourcepharma/attachments/20150905/61db0c33/attachment.html>